跳至主要内容
临床试验/ACTRN12614000895684
ACTRN12614000895684进行中(未招募)未知

MRI inflammation as an imaging biomarker in rheumatoid arthritis: comparing the change in MRI-inflammation scores between patients receiving treatment for disease flare with combination conventional disease suppressing therapy and those commencing combination methotrexate/anti-tumour necrosis factor (TNF) therapy

Prof Fiona McQueen0 个研究点目标入组 100 人开始时间: 2014年8月22日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • seropositive rheumatoid arthritis
  • Willing and eligible for disease modifying therapy including methotrexate, combination DAMRDS and /or anti-TNF therapy as per treating clinician's decision
  • Willing and eligible to have 2 contrast-enhanced MRI scans (no contraindications)

排除标准

  • Contraindications to the medical therapies for rheumatoid arthritis as outlined above
  • Patients will be excluded if there are contraindications to MRI scanning (obesity, claustrophobia, internal metalware) or have impaired renal function and cannot be given IV gadolinium (creatinine clearance must be > 60ml/min).

研究者

发起方
Prof Fiona McQueen

相似试验